Keywords: pdl, 3rd-qtr, loss, falls, despite, charges, third-quarter
PDL's 3rd-qtr loss falls 9% despite charges
Article | 26 November 2007
Third-quarter 2007 losses at USA-based biotechnology company PDL BioPharma narrowed 9.0% to $6.1 million, despite both a $4.5 million charge related to ongoing restructuring ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
